Cargando…

Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue

Precision oncology based on specific molecular alterations requires precise and reliable detection of therapeutic targets in order to initiate the optimal treatment. In many European countries—including Germany—assays employed for this purpose are highly diverse and not prescribed by authorities, ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vollbrecht, Claudia, Hoffmann, Inga, Lehmann, Annika, Merkelbach-Bruse, Sabine, Fassunke, Jana, Wagener-Ryczek, Svenja, Ball, Markus, Dimitrova, Lora, Hartmann, Arndt, Stöhr, Robert, Erber, Ramona, Weichert, Wilko, Pfarr, Nicole, Bohlmann, Lisa, Jung, Andreas, Dietmaier, Wolfgang, Dietel, Manfred, Horst, David, Hummel, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067656/ https://www.ncbi.nlm.nih.gov/pubmed/36367572 http://dx.doi.org/10.1007/s00428-022-03445-x

Ejemplares similares

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
por: Heydt, Carina, et al.
Publicado: (2021)

Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue
por: FASSUNKE, JANA, et al.
Publicado: (2015)

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
por: Heydt, Carina, et al.
Publicado: (2019)

Testung auf Mismatch-Reparatur-Defizienz und Mikrosatelliteninstabilität: Eine fokussierte Aktualisierung
por: Rüschoff, Josef, et al.
Publicado: (2023)

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
por: Alidousty, Christina, et al.
Publicado: (2018)

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL
por: Fassunke, Jana, et al.
Publicado: (2010)

First proficiency testing for NGS‐based and combined NGS‐ and FISH‐based detection of FGFR2 fusions in intrahepatic cholangiocarcinoma
por: Neumann, Olaf, et al.
Publicado: (2023)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
por: Scheffler, Matthias, et al.
Publicado: (2014)

Managing Difficulties of Microsatellite Instability Testing in Endometrial Cancer-Limitations and Advantages of Four Different PCR-Based Approaches
por: Siemanowski, Janna, et al.
Publicado: (2021)

Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics
por: Heydt, Carina, et al.
Publicado: (2014)

Molecular driver alterations and their clinical relevance in cancer of unknown primary site
por: Löffler, Harald, et al.
Publicado: (2016)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer
por: Arsenic, Ruza, et al.
Publicado: (2015)

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
por: Angelika Ihle, Michaela, et al.
Publicado: (2016)

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy
por: Heydt, Carina, et al.
Publicado: (2015)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Overview of Molecular Detection Technologies for MET in Lung Cancer
por: Heydt, Carina, et al.
Publicado: (2023)

Status quo of ALK testing in lung cancer: results of an EQA scheme based on in-situ hybridization, immunohistochemistry, and RNA/DNA sequencing
por: Jurmeister, Philipp, et al.
Publicado: (2021)

Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
por: Merkelbach-Bruse, Sabine, et al.
Publicado: (2010)

Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment
por: Budczies, Jan, et al.
Publicado: (2016)

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer
por: Anderson, Elizabeth J., et al.
Publicado: (2020)

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
por: Castiglione, Roberta, et al.
Publicado: (2018)

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
por: Kneissl, Julia, et al.
Publicado: (2016)

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells
por: Choi, Young Eun, et al.
Publicado: (2014)

Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative, PIK3CA-Mutated Advanced Breast Cancer
por: Diao, Fei-Yu
Publicado: (2021)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
por: Fillbrunn, Mirko, et al.
Publicado: (2022)

Diagnostik und Therapie von Tumoren mit NTRK-Genfusionen
por: Stenzinger, Albrecht, et al.
Publicado: (2020)

The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis
por: Wang, Mingming, et al.
Publicado: (2020)

Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2– Advanced Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
por: Straub, Melanie, et al.
Publicado: (2016)

Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy
por: Thelen, Martin, et al.
Publicado: (2021)

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
por: Kriegsmann, Mark, et al.
Publicado: (2014)

Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer
por: Kazdal, Daniel, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_aik23f426muc85blho5tabgt1n